Literature DB >> 29873848

Insulin Hexamer-Caged Gadolinium Ion as MRI Contrast-o-phore.

Steven K Taylor1, Timothy H Tran2, Michael Z Liu3, Paul E Harris1, Yanping Sun4, Sachin R Jambawalikar3, Liang Tong2, Milan N Stojanovic5.   

Abstract

High-relaxivity protein-complexes of GdIII are being pursued as MRI contrast agents in hope that they can be used at much lower doses that would minimize toxic-side effects of GdIII release from traditional contrast agents. We construct here a new type of protein-based MRI contrast agent, a proteinaceous cage based on a stable insulin hexamer in which GdIII is captured inside a water filled cavity. The macromolecular structure and the large number of "free" GdIII coordination sites available for water binding lead to exceptionally high relaxivities per one GdIII ion. The GdIII slowly diffuses out of this cage, but this diffusion can be prevented by addition of ligands that bind to the hexamer. The ligands that trigger structural changes in the hexamer, SCN- , Cl- and phenols, modulate relaxivities through an outside-in signaling that is allosterically transduced through the protein cage. Contrast-o-phores based on protein-caged metal ions have potential to become clinical contrast agents with environmentally-sensitive properties.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  contrast agent; environmentally sensitive; gadolinium; insulin hexamer; proteins

Mesh:

Substances:

Year:  2018        PMID: 29873848      PMCID: PMC6347121          DOI: 10.1002/chem.201801388

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  40 in total

1.  The structure of T6 human insulin at 1.0 A resolution.

Authors:  G David Smith; Walter A Pangborn; Robert H Blessing
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2003-02-21

2.  R6 hexameric insulin complexed with m-cresol or resorcinol.

Authors:  G D Smith; E Ciszak; L A Magrum; W A Pangborn; R H Blessing
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2000-12

Review 3.  Zinc-ligand interactions modulate assembly and stability of the insulin hexamer -- a review.

Authors:  Michael F Dunn
Journal:  Biometals       Date:  2005-08       Impact factor: 2.949

Review 4.  Next generation, high relaxivity gadolinium MRI agents.

Authors:  Kenneth N Raymond; Valérie C Pierre
Journal:  Bioconjug Chem       Date:  2005 Jan-Feb       Impact factor: 4.774

5.  Limit of blank, limit of detection and limit of quantitation.

Authors:  David A Armbruster; Terry Pry
Journal:  Clin Biochem Rev       Date:  2008-08

6.  Crystal structure of ultralente--a microcrystalline insulin suspension.

Authors:  Armin Wagner; Joachim Diez; Clemens Schulze-Briese; Gerd Schluckebier
Journal:  Proteins       Date:  2009-03

7.  Difficulties in determining accurate molecular motion parameters from proton relaxation enhancement measurements as illustrated by the immunoglobulin G-Gd(III) system.

Authors:  D R Burton; S Forsén; G Karlström; R A Dwek; A C McLaughlin; S Wain-Hobson
Journal:  Eur J Biochem       Date:  1976-12-11

8.  Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe.

Authors:  Simonetta Geninatti Crich; Benedetta Bussolati; Lorenzo Tei; Cristina Grange; Giovanna Esposito; Stefania Lanzardo; Giovanni Camussi; Silvio Aime
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

9.  X-ray structure of an unusual Ca2+ site and the roles of Zn2+ and Ca2+ in the assembly, stability, and storage of the insulin hexamer.

Authors:  C P Hill; Z Dauter; E J Dodson; G G Dodson; M F Dunn
Journal:  Biochemistry       Date:  1991-01-29       Impact factor: 3.162

10.  Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents.

Authors:  Peter Caravan; Christian T Farrar; Luca Frullano; Ritika Uppal
Journal:  Contrast Media Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.